Innate Pharma Reports Updated Share Capital and Voting Rights as of July 3, 2025
Marseille, France – July 4, 2025 – Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases, today announced the total number of its shares and voting rights as of July 3, 2025. This update, as reported by Business Wire French Language News, provides stakeholders with crucial information regarding the company’s current capital structure.
According to the official filing, as of July 3, 2025, Innate Pharma’s total number of shares amounts to 201,336,689. Each of these shares carries one voting right. Consequently, the total number of voting rights within the company also stands at 201,336,689.
This disclosure is in line with regulatory requirements and serves to ensure transparency for investors and the broader financial community. Understanding the precise number of shares and voting rights is fundamental for shareholders, particularly when considering their participation in general meetings or any potential corporate actions.
Innate Pharma continues to advance its robust pipeline of innovative therapeutic antibodies, focusing on novel mechanisms of action in both oncology and potentially other therapeutic areas. The company’s commitment to research and development remains a key driver of its strategic direction.
This latest update on the company’s share capital and voting rights is a routine but important communication, underscoring Innate Pharma’s dedication to maintaining open and accurate reporting to its shareholders and the market. Investors are encouraged to refer to the official filings for the most up-to-date information.
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 3 juillet 2025
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 3 juillet 2025’ at 2025-07-04 05:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.